What are the best RPM startups?

This blog post has been written by the person who has mapped the Remote Patient Monitoring startup market in a clean and beautiful presentation

Remote Patient Monitoring startups raised nearly $1 billion in 2024-2025, with AI-driven platforms leading the charge.

Corporate strategic investors from major healthcare companies are increasingly backing RPM innovations, creating partnerships that accelerate regulatory approval and market penetration. These investments signal a fundamental shift toward value-based healthcare delivery models.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

What is the current global landscape of RPM startups and who are the leading companies in this space today?

The RPM startup landscape is stratified into three distinct tiers based on clinical validation, regulatory readiness, and market scalability.

Top-tier innovators include Biofourmis (USA/Singapore) with AI-driven predictive analytics, Forward Health (USA) with integrated biometric remote clinics, and Element Science (USA/Europe) specializing in wearable defibrillators for arrhythmia care. These companies have achieved significant clinical validation and regulatory approval across multiple markets.

Second-tier players focus on specialized monitoring solutions: BioIntelliSense delivers continuous multi-vital monitoring through BioSticker and BioButton devices, while Implicity (Switzerland) operates cardiology trial-enablement platforms. IDOVEN (Spain) provides AI-enabled arrhythmia detection via ECG wearables, and Huma (UK) offers virtual care management with trial support capabilities.

Emerging leaders include Community Wellness (USA) with equity-focused chronic care engagement, Cloud DX (Canada) providing virtual wards and hospital-at-home solutions, and Neteera (Israel) pioneering radar-based contactless vital signs monitoring. These companies represent the next generation of RPM innovation with novel sensing modalities and care delivery models.

Geographic distribution shows U.S. dominance in funding and innovation, European leadership in contactless monitoring technologies, and emerging Asia-Pacific interest driven by aging population demographics.

Which RPM startups raised the most funding in 2024 and 2025 so far, and how much did they raise?

Eight RPM startups disclosed $971 million in total funding from January 2024 through June 2025, with two mega-rounds dominating the landscape.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Who are the key investors backing these leading RPM startups and what conditions or terms have they invested under?

Corporate strategic investors increasingly lead RPM funding rounds, often negotiating technology licensing rights and co-development agreements alongside equity stakes.

Philips Healthcare and Nordic Capital co-led Biofourmis's $463.6 million round with strategic partnership terms designed for European and U.S. market expansion. This deal includes board representation for Philips and milestone-based technology integration requirements. UPMC Enterprises and Labcorp anchored Percipio Health's Series A round, securing board representation and implementing milestone-based tranche releases tied to clinical validation milestones.

Corporate venture capital arms from major healthcare companies (Philips, Labcorp, Medtronic) participate as lead investors while negotiating technology licensing rights and co-development agreements. These strategic investors typically require deeper due diligence on regulatory pathways and reimbursement strategies compared to traditional VCs. Specialized health-tech venture capital firms like Menlo Ventures and Sands Capital structure rounds with standard board seats and performance-based options tied to device rollout milestones and patient enrollment targets.

Investment terms increasingly include regulatory milestone payments, with funding tranches released upon FDA clearance, CE marking, or specific clinical outcome achievements. Board composition typically includes one corporate strategic investor, one lead VC, and founder representation, with protective provisions around IP licensing and competitive restrictions.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Are any major industry giants or large corporations backing or partnering with RPM startups?

Major healthcare corporations actively invest in and partner with RPM startups through direct equity investments, co-development agreements, and strategic partnerships.

Philips Healthcare invested directly in Biofourmis while integrating its wearable biosensor technology into Philips' virtual care portfolio. This partnership includes joint go-to-market strategies and shared regulatory approval processes across European and U.S. markets. Labcorp joined Percipio Health's funding round to embed smartphone-based monitoring capabilities into its diagnostics network, creating new revenue streams through remote biomarker collection.

UPMC Enterprises backed Percipio Health to pilot RPM solutions across UPMC-affiliated hospitals, providing real-world clinical validation and potential acquisition pathways. Medical device giants including Medtronic and Philips form co-development partnerships with startups like Biofourmis and HealthSnap to bundle hardware and software solutions for comprehensive home care delivery.

These partnerships typically involve technology licensing agreements, joint clinical studies, and shared regulatory approval costs. Corporate partners provide market access, clinical validation opportunities, and regulatory expertise while startups contribute innovative technology platforms and agile development capabilities. The strategic value extends beyond capital to include distribution channels, clinical credibility, and accelerated market penetration.

Which RPM startups have received significant awards, recognition, or industry certifications recently?

RPM startups increasingly pursue industry awards and regulatory certifications to establish clinical credibility and accelerate market adoption.

Biofourmis received the 2024 IoT MedTech Breakthrough Award for its wearable biosensor innovation, recognizing the platform's integration of multi-vital monitoring with predictive analytics. Neteera secured CE Class IIa MDR certification in March 2025 following its U.S. FDA clearance in 2024, enabling commercial rollout across European markets for its radar-based contactless monitoring platform.

Multiple RPM startups including Element Science, BioIntelliSense, and Huma achieved rankings in Best in KLAS 2025 for RPM solutions, reflecting high customer satisfaction scores and clinical performance metrics from healthcare provider surveys. These recognition programs evaluate clinical outcomes, user experience, and provider satisfaction across implemented RPM programs.

Regulatory certifications carry particular weight in RPM market validation, with FDA clearance and CE marking serving as prerequisites for healthcare system adoption. Companies achieving dual regulatory approval demonstrate commitment to global market expansion and clinical quality standards that institutional buyers require for procurement decisions.

What are the most notable traits or differentiators of the top-performing RPM startups in 2025?

Top-performing RPM startups in 2025 differentiate through AI-driven predictive analytics, seamless device integration, contactless monitoring capabilities, and regulatory readiness combined with reimbursement pathway clarity.

AI-driven predictive analytics platforms like Biofourmis and IDOVEN leverage machine learning algorithms to forecast patient deterioration before clinical symptoms manifest. These systems analyze continuous physiological data streams to identify subtle pattern changes that predict adverse events, enabling proactive clinical interventions that reduce hospitalizations and improve patient outcomes.

Device integration and usability breakthroughs eliminate traditional patient friction points. HealthSnap's cellular-only devices remove smartphone dependency requirements, while Percipio Health's smartphone-camera biomarkers eliminate dedicated hardware needs entirely. These solutions address compliance challenges that historically limited RPM program effectiveness in elderly and technology-averse patient populations.

Contactless monitoring technologies, exemplified by Neteera's radar-based platform, offer completely unintrusive vital sign tracking without requiring patients to wear devices or remember to take measurements. This technology captures heart rate, respiratory rate, and movement patterns through wall-mounted sensors that monitor patients during normal daily activities.

Regulatory and reimbursement readiness accelerates provider adoption through established CPT code support, FDA clearance, CE marking, and demonstrated clinical outcomes that satisfy payer requirements. Companies like Cloud DX and CoachCare provide comprehensive documentation packages that streamline healthcare system procurement processes and reduce implementation timelines.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What technologies or R&D breakthroughs have these startups achieved recently and what breakthroughs are expected in 2026?

Recent RPM R&D breakthroughs focus on expanding monitoring capabilities beyond traditional vital signs while anticipated 2026 developments center on hybrid ecosystem integration and novel biomarker detection.

Biofourmis expanded its platform to assess endometriosis pain through biosensor data analytics, winning pharmaceutical co-development agreements in 2025 for chronic pain management applications. This breakthrough demonstrates RPM's evolution from acute care monitoring to complex chronic condition management with subjective symptom quantification capabilities.

Neteera advances radar signal processing technology to capture microscopic skin movements, with feasibility studies underway in German hospitals for detecting early signs of respiratory distress and cardiac irregularities. Their contactless monitoring achieves clinical-grade accuracy without patient compliance requirements, representing a fundamental shift in monitoring methodology.

Expected 2026 breakthroughs include hybrid ecosystems combining RPM with telehealth platforms for integrated care delivery, novel biomarker detection via smartphone sensors including hydration levels and stress indicators, and integration with virtual ICU platforms for acute care monitoring in home settings. Machine learning models will incorporate social determinants of health data to predict patient outcomes with greater accuracy than physiological monitoring alone.

Additional anticipated developments include edge computing integration for real-time processing, 5G connectivity enabling high-fidelity video monitoring, and AI-powered clinical decision support that automatically adjusts treatment protocols based on continuous monitoring data streams.

How much total capital has been invested in the RPM startup sector in 2024 and 2025 so far?

RPM startups raised $971 million in disclosed funding from January 2024 through June 2025, with U.S.-based companies capturing 95% of total investments.

This funding level represents a significant concentration in mega-rounds, with Biofourmis ($463.6 million) and Forward Health ($325 million) accounting for 81% of total disclosed investment. The remaining $182.4 million distributed across six additional startups indicates selective investor focus on market leaders with proven clinical validation and regulatory approval.

Geographic distribution shows U.S. market dominance driven by favorable reimbursement environments, established CPT codes for RPM services, and mature healthcare system adoption. European companies like Neteera and IDOVEN secured funding through private rounds, though specific amounts remain undisclosed for competitive reasons.

Investment concentration in fewer, larger rounds reflects market maturation and investor preference for companies with clear paths to profitability through healthcare system contracts and payer reimbursement agreements. This trend suggests continued consolidation around established platforms rather than broad-based funding across numerous early-stage startups.

Which RPM startups show the strongest traction and growth potential based on geography or regional markets?

North America dominates RPM startup traction with 95% of disclosed funding, driven by established reimbursement frameworks and healthcare system adoption, while Europe emerges as an innovation hub for contactless monitoring technologies.

North American RPM startups benefit from comprehensive payer reimbursement through CPT codes 99453-99458, which provide clear revenue pathways for healthcare providers implementing RPM programs. This regulatory clarity enables startups like Biofourmis, Forward Health, and HealthSnap to scale rapidly through direct healthcare system contracts and Medicare/Medicaid reimbursement.

European startups demonstrate strong innovation traction in contactless and radar-based monitoring technologies, with companies like Neteera (Israel), IDOVEN (Spain), and Implicity (Switzerland) achieving CE certification and pilot programs in government-backed hospital-at-home initiatives. European healthcare systems increasingly embrace RPM as a solution for aging population management and healthcare cost reduction.

Asia-Pacific markets show growing interest in RPM solutions driven by rapidly aging populations, particularly in Japan and South Korea, though limited disclosed investment activity suggests early-stage market development. Singapore-based operations like Biofourmis indicate strategic positioning for regional expansion as regulatory frameworks mature.

Regional growth potential correlates directly with reimbursement policy development, with markets offering clear RPM reimbursement pathways attracting the highest startup activity and investment capital.

If you want actionable data about this market, you can download our latest market pitch deck here

Which RPM startups are attracting repeat or follow-on funding rounds and who are the most active investors?

Established RPM platforms attract repeat funding from strategic corporate investors and specialized health-tech venture capital firms, indicating sustained confidence in market leaders with proven clinical outcomes.

Biofourmis demonstrates the strongest repeat investor commitment, securing multiple funding rounds since 2018 from Philips Healthcare and Nordic Capital. This ongoing investment relationship reflects successful clinical validation milestones and regulatory approval achievements that justify continued capital allocation. HealthSnap and Solace attracted follow-on rounds from Sands Capital and Menlo Ventures respectively, with investors increasing position sizes based on demonstrated patient engagement metrics and provider adoption rates.

Most active investors include corporate venture capital arms from major healthcare companies (Philips, Labcorp, UPMC), specialized health-tech funds (Menlo Ventures, Sands Capital, Integrity Growth Partners), and healthcare system investment arms seeking strategic technology partnerships. These investors typically provide 18-24 month development capital with milestone-based releases tied to regulatory approvals and clinical outcome achievements.

Follow-on funding patterns indicate investor preference for companies demonstrating clear paths to profitability through healthcare system contracts and payer reimbursement agreements. Repeat investors often negotiate increased board representation and technology licensing rights as investment relationships deepen and strategic value becomes clearer.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

What can be expected in terms of overall funding trends and capital allocation in the RPM space for 2026?

2026 RPM funding trends will emphasize consolidation through M&A activity, increased allocation to AI-embedded platforms, and value-based partnerships between RPM vendors and payers seeking outcome-linked contracts.

Market consolidation will accelerate as established telehealth platforms acquire specialized device manufacturers to create comprehensive care delivery ecosystems. Larger RPM companies with proven clinical outcomes and regulatory approval will acquire smaller startups with innovative sensing technologies or specialized clinical applications, similar to traditional medical device industry consolidation patterns.

Investment allocation will shift toward startups with advanced predictive analytics capabilities, as healthcare systems demand RPM solutions that prevent adverse events rather than simply monitoring vital signs. AI-embedded platforms that demonstrate measurable reductions in hospitalizations and emergency department visits will attract premium valuations and strategic corporate investment.

Value-based partnership structures will become standard, with increased investments from payers and pharmaceutical companies seeking outcome-linked contracts with RPM vendors. These partnerships will include risk-sharing arrangements where RPM companies receive payment based on achieved clinical outcomes and cost savings rather than traditional fee-for-service models.

Geographic expansion funding will target European and Asia-Pacific markets as regulatory frameworks mature and government-backed healthcare initiatives create clearer market opportunities for RPM adoption.

What other promising RPM startups, not yet dominant, are emerging with innovative approaches or disruptive models?

Emerging RPM startups combine AI-powered smartphone applications, automated workflow optimization, and specialized clinical focus areas that may disrupt established monitoring paradigms.

Conclusion

Sources

1. Remote Patient Monitoring Funding Analysis
2. RPM Startups Market Overview Video
3. LinkedIn RPM Global Startups Analysis
4. Neteera CE MDR Certification Announcement
5. Biofourmis Innovation Recognition
6. Best in KLAS Remote Patient Monitoring Rankings 2025
7. Top Remote Patient Monitoring Companies Analysis
8. Emerging Patient Monitoring Solutions Report